Abstract
In nuclear medicine, multiple peptide receptors are recognized as potential
diagnostic and therapeutic targets. 68Ga-NT-20.3 radiopharmaceutical has been
developed for diagnosis of neurotensin receptors. Three neurotensin receptors subtypes
have been cloned: NTR-1, NTR-2 and NTR-3. NTR-1 is the most commonly expressed
neurotensin receptor. High NTR-1 expression has been observed in various tumours
including pancreatic ductal adenocarcinoma. 68Ga-labelled NT ligand was successfully
applied in in vitro, animal model as well as in human. The results on humans
demonstrated that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.
Based on the published data, NTR-1 is promising target for the development of
radioactive analogues for both imaging and therapy in patients with primary and
metastatic pancreatic ductal adenocarcinoma.
Keywords: 68Ga-NT-20.3, Neurotensin, Neurotensin receptor, Pancreatic cancer, PET.
Related Books
Advances in Cancer Nanotheranostics for Experimental and Personalized Medicine
Cancer Metastasis and Cancer Stem Cell/Niche
Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature
Controversies in Neuro-Oncology
Current Advances in Breast Cancer Research: A Molecular Approach
Cutting Edge Therapies for Cancer in the 21st Century
Frontiers in Cancer Immunology
Frontiers in Cancer Immunology
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Frontiers in Clinical Drug Research - Anti-Cancer Agents